|
|
||||
|
|
||||
|
||||
Clinical Neuro-Oncology |
Departments of Neurobiology and Developmental Sciences (Y.-H.Z., L.L.), Neurological Surgery (Y.-H.Z.), Radiation Oncology (Y.-H.Z.), and Epidemiology (L.L.), Arkansas Cancer Research Center (Y.-H.Z., L.L.), University of Arkansas for Medical Sciences, Little Rock, AR 72205; Departments of Biostatistics (K.R.H.) and Neuro-Oncology (W.K.A.Y.), University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; Department of Neurological Surgery, University of California (M.E.L.), Irvine, CA 92868; USA
2 Address correspondence to Yi-Hong Zhou, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 753, Little Rock, AR 72205, USA (yzhou{at}uams.edu).
Abstract
The disparate lengths of survival among patients with malignant astrocytic gliomas (anaplastic astrocytomas [AAs] and glioblastoma multiforme [GBM]) cannot be adequately accounted for by clinical variables (patient age, histology, and recurrent status). Using real-time quantitative reverse transcription-polymerase chain reaction, we quantified the expression of four genes that were putative prognostic markers (CDK4, IGFBP2, MMP2, and RPS9) in a set of 43 AAs, 41 GBMs, and seven adjacent normal brain tissues. We previously explicated the expression and prognostic value of PAX6, PTEN, VEGF, and EGFR in these glioma tissues and established a comprehensive prognostic model (Zhou et al., 2003). This study attempts to improve that model by including four additional genetic markers, which exhibited a differential expression (P < 0.001) among tumor grades and between tumor and normal tissues. By including eight log-scaled gene expression variables, three clinical variables, and interaction terms among the eight genes, we established a prognostic model that accounted for two thirds of the variation (R2) in survival for this set of patients. To improve the R2 of the model without compromising its clinical utility, our data demonstrated that incorporating genes from different pathways markedly strengthens the model. Spearman rank correlation analysis of gene expression demonstrated a statistically significant positive correlation (P < 0.01) between the expression of IGFBP2-MMP2 and IGFBP2-VEGF in GBMs, but not in AAs. This finding suggests that the expression of IGFBP2 is associated with pathways activated specifically in GBMs that result in enhancing invasiveness and angiogenesis.
This article has been cited by other articles:
![]() |
T. Fukushima, T. Tezuka, T. Shimomura, S. Nakano, and H. Kataoka Silencing of Insulin-like Growth Factor-binding Protein-2 in Human Glioblastoma Cells Reduces Both Invasiveness and Expression of Progression-associated Gene CD24 J. Biol. Chem., June 22, 2007; 282(25): 18634 - 18644. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Heister, A. Hayar, A. Charlesworth, C. Yates, Y.-H. Zhou, and E. Garcia-Rill Evidence for Electrical Coupling in the SubCoeruleus (SubC) Nucleus J Neurophysiol, April 1, 2007; 97(4): 3142 - 3147. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Mayes, Y. Hu, Y. Teng, E. Siegel, X. Wu, K. Panda, F. Tan, W.K. A. Yung, and Y.-H. Zhou PAX6 Suppresses the Invasiveness of Glioblastoma Cells and the Expression of the Matrix Metalloproteinase-2 Gene. Cancer Res., October 15, 2006; 66(20): 9809 - 9817. [Abstract] [Full Text] [PDF] |
||||
|
|